Baxter International Inc. has announced significant safety concerns related to its Novum LVP infusion device, following reports of inaccurate infusion rates. The company issued warning letters to customers in April and July 2025, disclosing a total of 79 serious injury reports and two patient deaths connected to the device. Despite these reports, Baxter initially continued to instruct hospitals on corrective steps rather than removing the devices from service. On July 31, 2025, Baxter voluntarily and temporarily paused all shipments and planned installations of the Novum LVP, citing quality concerns identified through customer feedback and internal data. This announcement led to a sharp decline in Baxter's stock price, falling over 22% in a single day.